drugset / Trial / NCT00644800

A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of Psychosis

NCT00644800

Phase 4 Completed 89 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the efficacy, safety, and tolerability of intramuscular ziprasidone in the treatment of the acute exacerbation of non-organic psychosis of any etiology, including schizophrenia, acute mania, delusional disorder and others.

Timeline

Start
2003-07
Primary completion
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziprasidone Small molecule 40 mg Intramuscular
Subject Ziprasidone Small molecule 80 mg Intramuscular